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Background:  The  aim  of this  study  was  to investigate  the  effect  of  a levosimendan  infusion  on  hematolog-
ical  variables  in  patients  with  acute  decompensated  heart  failure  (ADHF).  The  predictive  value  of  these
variables  for in-hospital  mortality  was  also  evaluated.
Methods: A  total  of  553  patients  (368 males;  mean  age,  63.4  ± 14.9 years)  with  acute  exacerbations  of
advanced  heart  failure  (ejection  fraction  ≤35%)  and  treated  with  either  dobutamine  or  levosimendan  were
included  in  this  retrospective  analysis.  The  patients  that  received  levosimendan  therapy  were  divided
into  two  groups  according  to in-hospital  mortality:  group  1 (21%)  included  patients  who  died during
hospitalization  (n = 45),  while  group  2  (79%)  included  patients  with  a favorable  outcome  (n =  174)  after
levosimendan  infusion.  Changes  in several  hematological  variables  between  admission  and  the third  day
after  levosimendan  infusion  were  evaluated.
Results: The  demographic  characteristics  and  risk factors  of  the  two  groups  were  similar.  A comparison
of  changes  in laboratory  variables  after  the  infusion  of  levosimendan  revealed  signiﬁcant  improvement
only  in  those  patients  who  had  not  died  (group  2) during  hospitalization.  The  neutrophil  to  lymphocyte
(N/L)  ratio  after  levosimendan  infusion  was  an  independent  predictor  of  in-hospital  mortality  (odds
ratio:  1.310,  95%  CI:  1.158–1.483,  p < 0.001).  In a receiver-operating  characteristic  curve analysis,  a value
of 5.542  for  the  N/L ratio after  levosimendan  administration  was  identiﬁed  as  an effective  cut-off  point
for  predicting  in-hospital  mortality  (area  under  the  curve  =  0.737;  95%  conﬁdence  interval  = 1100–1301;
p  <  0.001).
Conclusions:  Levosimendan  treatment  was  associated  with  signiﬁcant  changes  in  hematological  variables
in patients  with  ADHF.  A  sustained  higher  N/L ratio  after levosimendan  infusion  is  associated  with  an
increased  risk  of  in-hospital  mortality  in  patients  with  ADHF.
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Heart failure (HF) is a complex syndrome rather than an
xclusive problem of low cardiac output. Neurohormonal and
nﬂammatory activation, particularly involving polymorphonu-
lear leukocytes, is thought to play a key role in the pathophysiology
f HF [1]. An association between increased white blood cell (WBC)
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counts and a high incidence of HF-related hospitalization and
mortality has been reported [2,3]. Additionally, the neutrophil-
to-lymphocyte (N/L) ratio is a well-known prognostic marker
in patients with coronary artery disease or in those undergo-
ing coronary angiography, percutaneous coronary intervention,
and coronary artery bypass grafting [4,5]. In parallel, neutrophilia
has been found to be associated with an increased incidence of
acute decompensated HF (ADHF) in patients with acute myocar-
dial infarction [6], while relative lymphocytopenia has been shown
to be an independent predictor of mortality in HF patients [7–10].
Recently, a higher N/L ratio on hospital admission was  shown to be
associated with an increased risk of short- and long-term morbidity
and mortality in patients with ADHF [11].
vier Ltd. All rights reserved.
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Levosimendan, a Ca2+ sensitizer that increases troponin-C sensi-
ivity to cytoplasmic Ca2+ without modifying the intracellular Ca2+
ensity, improves cardiac performance and decreases systemic and
ascular resistance and proinﬂammatory marker levels [12–16].
owever, no data exist regarding the effect of a levosimendan
nfusion on the N/L ratio and its utility in predicting in-hospital
ortality for patients with ADHF. The aims of this study were to
valuate the effects of levosimendan infusion on hematological
ariables and the association between the N/L ratio after levosi-
endan infusion and in-hospital mortality in patients with ADHF.
e also compared the discriminative prognostic efﬁcacy of these
ematological variables with that of other variables at baseline and
fter the infusion of levosimendan. To our knowledge, our study
s the ﬁrst to investigate the effects of levosimendan on the WBC
ount and the prognostic value of the N/L ratio after levosimendan
nfusion in ADHF patients.
aterials and methods
atient population
We  retrospectively evaluated a total of 1061 consecutive
atients who were admitted (from January 2011 to April 2013) to
ezmialem Foundation University Hospital (Istanbul) and Mehmet
kif Ersoy Thoracic-Cardiovascular Surgery Training and Research
ospital (Istanbul) with ADHF [ejection fraction ≤ 35% and New
ork heart Association (NYHA) Class IV]. Patients were analyzed
n two groups according to positive inotropic treatment that they
ad received such as, levosimendan or dobutamine. Patients with
edical conditions known to affect the total and differential WBC
ounts, such as: disorders of the hematopoietic system, history
f cancer and/or previous treatment with chemotherapy, infec-
ion, and chronic inﬂammatory conditions; glucocorticoid therapy
nd/or histories of glucocorticoid use 3 months before the admis-
ion; and acute myocardial infarction or coronary revascularization
ithin the past 6 months; and patients with incomplete data were
xcluded from the study. Also, patients who did not have both
BC counts before and after levosimendan infusion were excluded
Fig. 1). The study protocol was approved by the hospitals’ ethics
ommittees.nalysis of patient data
Data included demographic characteristics, laboratory data,
edications, and echocardiographic parameters collected by the
Fig. 1. Flow chart of the patients enrolled in the study. WBC, white blood cell.logy 63 (2014) 418–423 419
study personnel from the hospitals’ medical records. Clinical risk
factors such as age, sex, diabetes mellitus (DM), hypertension (HT),
hypercholesterolemia, smoking, and history of cardiovascular dis-
ease were determined. Body mass index (BMI) was  calculated as
the weight in kilograms divided by the square of the height in
meters. The left ventricular end systolic and diastolic diameters
(LVESD, LVEDD), and ejection fraction (LVEF) measured before
and after levosimendan therapy with transthoracic echocardiog-
raphy were recorded. Complete blood counts which included total
WBCs, neutrophils, and lymphocytes, and routine biochemical tests
results were obtained and N/L ratio was calculated as the ratio of
the neutrophil to lymphocytes, from the same automated blood
sample before and after levosimendan infusion on the third day.
Also, the serum high sensitivity C-reactive protein (hsCRP) lev-
els, which were obtained with the nephelometric method, using
a Dade Behring Cardio Phase kit (Dade Behring Inc., Newark, DE,
USA) were recorded on admission and after levosimendan infusion.
Death from any cause during hospitalization was  the primary end
point. Association between proportion of changes in hematological
variables after levosimendan infusion were evaluated. Additionally,
the independent association of different hematological variables
with in-hospital mortality was  analyzed.
Statistical analyses
Categorical variables were expressed as frequencies and per-
centages. Chi-square tests were used to compare categorical
variables. Univariate and a backward stepwise multivariate logis-
tic regression analysis, was performed to evaluate the independent
predictors of in-hospital cardiovascular mortality. To analyze the
association of N/L ratio with in-hospital mortality, continuous
variables were compared using analysis of covariance when base-
line variables were presumed as a covariate for those with skewed
distributions. A logistic regression model was  used to analyze the
independent association of N/L ratio. The Kaplan–Meier curve
and log-rank test were used to compare time to event distributions.
A p-value < 0.05 was considered statistically signiﬁcant. Statisti-
cal analyses were performed using SPSS version 15.0 for Windows
(SPSS, Inc., Chicago, IL, USA).
Results
A total of 219 consecutive eligible patients (mean age,
63.2 ± 12.7 years; 168 males, 51 females) that received lev-
osimendan were included in this retrospective study. Also, 334
patients that underwent dobutamine therapy were analyzed as
a control group. After the levosimendan infusion, a signiﬁcant
increase in the LVEF (26.7 ± 5.8% vs. 29.2 ± 5.4%, p < 0.001) and
lymphocyte count (1.3 ± 0.7 × 1000/l  vs. 1.5 ± 0.7 × 1000/l,
p = 0.03) and signiﬁcant decreases in the LVESD (49.1 ± 4.9 cm
vs. 47.1 ± 4.5 cm,  p = 0.02), WBC  count (9.6 ± 3.7 × 1000/l  vs.
9.2 ± 3.8 × 1000/l,  p = 0.02), neutrophil count (7.2 ± 3.6 × 1000/l
vs. 6.8 ± 3.7 × 1000/l,  p = 0.004), hsCRP (7.6 ± 4.8 ng/ml vs.
5.9 ± 3.1 ng/ml, p < 0.001), and creatinine level (1.3 ± 0.5 mg/dl
vs. 1.2 ± 0.5 mg/dl, p = 0.005) were observed (Table 1). How-
ever, favorable changes in hematological variables were not
seen in patients that received dobutamine therapy (Table 1).
The patients that received levosimendan infusion were divided
into two  groups according to in-hospital mortality: group 1
(21%) included patients who  died during hospitalization (n = 45),
while group 2 (79%) included patients with a favorable outcome
(n = 174) after levosimendan infusion. The demographic charac-
teristics and risk factors of the two groups were similar (Table 2).
There was  no signiﬁcant difference in the medications that the
patients received during hospitalization. An analysis of laboratory
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Table  1
Effects of levosimendan and dobutamine on hemodynamic, echocardiographic, and laboratory variables.
Levosimendan
n = 219
Dobutamine
n = 334
Before infusion After infusion p Before infusion After infusion p
Hemodynamic variables
Heart rate (beats/min) 75.9 ± 16.7 81.5 ± 19.8 0.22 79.1 ± 12.8 78.4 ± 11.9 0.48
Systolic BP (mmHg) 104.6 ± 5.9 104.2 ± 5.5 0.97 108.9 ± 7.6 114.3 ± 8.7 0.23
Diastolic BP (mmHg) 62.5 ± 4.7 62.2 ± 4.0 0.98 69.5 ± 8.4 73.6 ± 9.2 0.31
Echocardiographic variables
LVEF (%) 26.7 ± 5.8 29.2 ± 5.4 <0.001 27.1 ± 6.1 28.9 ± 5.4 0.04
LVESD (mm) 49.1 ± 4.9 47.1 ± 4.5 0.02 51.5 ± 5.1 50.8 ± 4.9 0.88
LVEDD (mm) 61.4 ± 5.1 60.9 ± 4.8 0.76 62.4 ± 6.1 62.3 ± 6.0 0.81
Laboratory variables
WBC  count (×1000/l) 9.6 ± 3.7 9.2 ± 3.8 0.02 10.3 ± 3.9 10.5 ± 4.1 0.48
Neutrophil count (×1000/l) 7.2 ± 3.6 6.8 ± 3.7 0.004 7.2 ± 2.0 7.8 ± 1.6 0.32
Lymphocyte count (×1000/l) 1.3 ± 0.7 1.5 ± 0.7 0.03 1.7 ± 0.9 1.8 ± 1.0 0.31
Hemoglobin (mg/dl) 11.4 ± 1.9 11.3 ± 2.2 0.34 11.1 ± 2.4 11.4 ± 2.1 0.14
Platelet count (×1000/l) 246.4 ± 100.2 243.8 ± 95.7 0.56 196.2 ± 69.4 194.3 ± 83.1 0.87
Creatinine (mg/dl) 1.3 ± 0.5 1.2 ± 0.5 0.005 1.3 ± 0.4 1.4 ± 0.4 0.83
hsCRP (ng/ml) 7.6 ± 4.8 5.9 ± 3.1 <0.001 6.9 ± 5.7 8.2 ± 6.2 0.28
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bP, blood pressure; LVEF, left ventricular ejection fraction; LVESD, left ventricular en
ell;  hsCRP, high-sensitivity C-reactive protein.
arameters before the infusion of levosimendan demonstrated
hat being in group 1 was associated with a lower lymphocyte
ount (1.3 ± 0.6 × 1000/l  vs. 1.4 ± 0.7 × 1000/l,  p = 0.005) and
 higher WBC  count, neutrophil count, N/L ratio, and creati-
ine level (12.2 ± 4.8 × 1000/l  vs. 8.9 ± 3.1 × 1000/l,  p < 0.001;
.8 ± 4.7 × 1000/l  vs. 6.6 ± 2.9 × 1000/l,  p = 0.001; 10.2 ± 8.4 vs.
.1 ± 5.3, p < 0.001; and 1.5 ± 0.5 mg/dl vs. 1.3 ± 0.5 mg/dl, p = 0.009,
espectively). A comparison of changes in laboratory variables
fter the infusion of levosimendan demonstrated a meaningful
able 2
aseline demographic characteristics and laboratory values of the study population.
Group 1
n = 45
Group 2
n = 174
p
Age (years) 65.4 ± 11.2 62.5 ± 12.9 0.17
Gender (male) (%) 31 (68.9) 137 (78.7) 0.16
BMI  (kg/m2) 23.0 ± 4.6 25.3 ± 3.5 0.41
Current smoker (%) 5 (11.1) 21 (12.0) 0.86
Hypertension (%) 23 (51.1) 87 (50.0) 0.99
Diabetes mellitus (%) 16 (35.5) 53 (30.4) 0.51
Dyslipidemia (%) 15 (33.3) 63 (36.2) 0.12
Previous coronary artery bypass
graft (%)
7 (15.5) 20 (11.5) 0.44
Cause of HF
(ischemic/nonischemic)
35/10 130/44 0.71
Heart rate (beats/min) 75.9 ± 16.7 81.5 ± 19.8 0.22
Systolic BP (mmHg) 104.6 ± 5.9 104.2 ± 5.5 0.97
Diastolic BP (mmHg) 62.5 ± 4.7 62.2 ± 4.0 0.98
LVEF (%) 25.9 ± 5.8 26.9 ± 5.4 0.31
WBC  count (×1000/l) 12.2 ± 4.8 8.9 ± 3.1 <0.001
Neutrophil count (×1000/l) 9.8 ± 4.7 6.6 ± 2.9 0.001
Lymphocyte count (×1000/l) 1.3 ± 0.6 1.4 ± 0.7 0.005
Neutrophil-to-lymphocyte ratio 10.2 ± 8.4 6.1 ± 5.3 <0.001
Serum sodium (mequiv./l) 135 ± 3 133 ± 4 0.29
Creatinine (mg/dl) 1.5 ± 0.5 1.3 ± 0.5 0.009
hsCRP (ng/ml) 8.2 ± 5.2 7.5 ± 4.7 0.46
Medications
ACEI or ARB (%) 41 (92) 154 (89) 0.62
ˇ  blocker (%) 43 (97) 164 (94) 0.73
Digoxin (%) 31 (68) 109 (63) 0.44
Spironolactone (%) 42 (93) 165 (95) 0.40
Furosemide (%) 45 (100) 174 (100) 1.00
Levosimendan (%) 45 (100) 174 (100) 1.00
Nitroglycerine (%) 8 (18) 26 (15) 0.64
MI, body mass index; HF, heart failure; BP, blood pressure; LVEF, left ventricular
jection fraction; WBC, white blood cell; hsCRP, high-sensitivity C-reactive pro-
ein; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor
lockers.olic dimension; LVEDD, left ventricular end-diastolic dimension; WBC, white blood
improvement in only those patients who  had not died (group 2)
during hospitalization (Table 3). The N/L ratio after the infusion
of levosimendan was identiﬁed as an independent predictor of
in-hospital mortality when all hemodynamic, hematological, and
biochemical variables associated with mortality were subjected to
a multivariate logistic regression analysis [odds ratio: 1.310, 95%
conﬁdence interval (CI): 1.158–1.483, p < 0.001] (Table 4).
In a receiver-operating characteristic curve analysis, a value
of 5.542 for the N/L ratio after levosimendan administration was
identiﬁed as an effective cut-off point for predicting in-hospital
mortality (area under the curve = 0.737, 95% CI = 1100–1301,
p < 0.001) in patients with ADHF. An N/L ratio value of >5.542
yielded a sensitivity of 67% and a speciﬁcity of 66% (Fig. 2). A signif-
icant association was noted between a high N/L ratio (≥5.542) and
earlier in-hospital all-cause mortality compared to patients with
lower N/L ratio (12 ± 7 days vs. 22 ± 12 days, respectively, p = 0.002;
Fig. 3).
Discussion
Our study revealed that an unchanging or increasing N/L ratio
after the infusion of levosimendan was  associated with in-hospital
mortality in patients admitted to the hospital with ADHF. Further-
more, the predictive value of the N/L ratio was superior to that of
other hematological variables.
Inﬂammatory processes are involved in the pathophysiology of
HF and portent a worsening functional capacity and poor progno-
sis; thus, inﬂammation is currently considered to be a therapeutic
target in HF [17]. The WBC  count is a marker of systemic inﬂam-
mation, but data on its association with an increased risk of HF
are limited [2,18]. However, cytokines, which are associated with
the development, progression, and unfavorable outcomes in HF,
are secreted by mainly leukocytes [19–21]. Neutrophilia, lympho-
cytopenia, and particularly an increase in the N/L ratio, have been
shown to be independent predictors of mortality in patients with
ADHF [10,11,15]. Downregulation of the proliferation and differen-
tiation of lymphocytes, neurohumoral activation, and lymphocyte
apoptosis have been suggested as potential mechanisms of lym-
phocytopenia [15]. Likewise, in our study, patients with ADHF had
a lower lymphocyte count on admission. After the infusion of lev-
osimendan, a dramatic increase was  detected in patients with a
favorable outcome compared to patients who experienced death.
We  suggest that a deterioration in the lymphocyte count after the
A. Tasal et al. / Journal of Cardiology 63 (2014) 418–423 421
Table  3
Comparison of hemodynamic, echocardiographic, and laboratory variable changes after levosimendan infusion between two groups.
Group 1 (n = 45) Group 2 (n = 174) F p
Before LS After LS Before LS After LS
Hemodynamic variables
Heart rate (beats/min) 78.6 ± 6.8 81.9 ± 6.8 77.0 ± 5.2 80.5 ± 5.2 0.1 0.80
Systolic BP (mmHg) 104.7 ± 5.7 98.5 ± 4.4 104.2 ± 5.5 99.3 ± 4.7 1.1 0.29
Diastolic BP (mmHg) 62.5 ± 4.7 61.7 ± 3.6 62.2 ± 4.0 61.1 ± 4.1 1.0 0.31
Echocardiographic variables
LVEF (%) 25.9 ± 5.8 28.5 ± 5.3 26.9 ± 5.4 29.3 ± 4.7 1.2 0.28
LVESD (mm)  48.2 ± 4.2 45.2 ± 4.1 47.5 ± 4.9 44.3 ± 4.3 2.1 0.15
LVEDD (mm) 62.5 ± 5.1 61.4 ± 4.8 61.2 ± 4.4 60.4 ± 5.1 0.9 0.33
Laboratory variables
WBC  count (×1000/l) 12.2 ± 4.8 12.1 ± 5.4 8.9 ± 3.1 8.5 ± 2.9 1.8 0.18
Neutrophil count (×1000/l) 9.8 ± 4.7 10.0 ± 5.4 6.6 ± 2.9 5.9 ± 2.5 17.8 <0.001
Lymphocyte count (×1000/l) 1.3 ± 0.6 1.2 ± 0.6 1.4 ± 0.7 1.5 ± 0.7 9.5 0.002
Neutrophil-to-lymphocyte ratio 10.2 ± 8.4 12.9 ± 14.3 6.2 ± 5.3 5.1 ± 3.4 24.9 <0.001
Creatinine (mg/dl) 1.5 ± 0.5 1.6 ± 0.7 1.3 ± 0.5 1.2 ± 0.4 15.4 <0.001
hsCRP (ng/ml) 8.2 ± 5.2 6.8 ± 3.0 7.5 ± 4.7 5.6 ± 3.1 5.7 0.02
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CS, levosimendan; BP, blood pressure; LVEF, left ventricular ejection fraction; LVESD
BC,  white blood cell; hsCRP, high-sensitivity C-reactive protein.
nfusion of levosimendan can be used to predict in-hospital mor-
ality. Recently, Uthamalingamet al. [11] showed that a higher N/L
atio was associated with an increased risk of mortality in patients
ith ADHF. Furthermore, the ability of the N/L ratio to predict mor-
ality in these patients was superior to that of the neutrophil count,
otal WBC  count, or a relatively low lymphocyte count. The authors
id not mention whether their patients had received levosimendan
r the potential effects of levosimendan on hematological variables.
alculation of the N/L ratio is simple and inexpensive compared
ith the measurement of proinﬂammatory cytokines, including
nterleukin (IL)-6, IL-1, and tumor necrosis factor (TNF)- [20,21].
Several studies have suggested that levosimendan causes a
arked decrease in the levels of proinﬂammatory compounds such
s brain natriuretic peptide (BNP), IL-6, and TNF- [22–24]. Lev-
simendan also provided hemodynamic and clinical improvement
n patients with ADHF [22–24]. It has been suggested that the
melioration of hemodynamic parameters may  partly explain the
ecreased expression of these mediators in the myocardium [25].
n another study, superiority of levosimendan over dobutamine in
mproving hemodynamics was related to its anti-inﬂammatory and
nti-apoptotic effects [26]. Additionally, levosimendan-induced
able 4
nivariate and multivariate logistic regression analysis for variables associated with in-h
Univariable predictors 
 ˇ coefﬁcient OR 95% CI 
Age (years) 0.02 1.020 0.992–1.048 
Hypertension (%) −0.002 0.998 0.518–1.924 
Diabetes mellitus (%) 0.23 1.260 0.631–2.513 
Ischemic cardiomyopathy (%) 0.15 1.158 0.529–2.533 
Baseline
Neutrophil-to-lymphocyte ratio 0.09 1.092 1.038–1.149 
Creatinine (mg/dl) 0.80 2.235 1.205–4.147 
hsCRP  (ng/ml) 0.02 1.022 0.955–1.093 
Heart  rate (beats/min) 0.05 1.050 0.992–1.111 
Systolic BP (mmHg) 0.02 1.015 0.956–1.077 
Diastolic BP (mmHg) 0.02 1.018 0.941–1.102 
LVEF  (%) −0.03 0.969 0.913–1.030 
Final
Neutrophil-to-lymphocyte ratio 0.18 1.198 1.114–1.288 
Creatinine (mg/dl) 1.42 4.125 2.201–7.729 
hsCRP  (ng/ml) 0.13 1.136 1.021–1.265 
Heart  rate (beats/min) 0.06 1.065 1.007–1.131 
Systolic BP (mmHg) −0.04 0.960 0.888–1.038 
Diastolic BP (mmHg) 0.05 1.045 0.959–1.137 
LVEF  (%) −0.03 0.966 0.902–1.035 
I, conﬁdence interval; hsCRP, high-sensitivity C-reactive protein; LVEF, left ventricular eentricular end-systolic dimension; LVEDD, left ventricular end-diastolic dimension;
improvements in systolic function and peripheral vasorelaxation
may  attenuate peripheral tissue hypoperfusion leading to the
downregulation of extracardiac cytokine production [27,28]. In our
patients, there was  a signiﬁcant decrease in the neutrophil count
and N/L ratio, and an increase in the lymphocyte count after the
infusion of levosimendan. However, patients on dobutamine ther-
apy did not exhibit similar changes on hemotological parameters.
When the study population was divided into two  groups on the
basis of in-hospital mortality, the lymphocyte count was  lower
while the WBC  count, neutrophil count, and N/L ratio were higher,
on admission. In this study, the mortality rate was higher com-
pared to results of the previous similar studies [22,24,29]. Some of
the possible explanations for this issue could be increased age of
our study population (mean age 63.4 ± 14.9 years old), worst func-
tional status of the patients (all the patients were NYHA Class IV),
and ischemic etiology as the underlying pathology in most of the
patients (77%). Pereira-Barretto et al. recently published their in-
hospital mortality rate as 16% in a similar study group consisting
of patients with advanced heart failure (NYHA Class III/IV, mean
LVEF 26%) [29]. After the infusion of levosimendan, a signiﬁcant
increase in the lymphocyte count and signiﬁcant decreases in the
ospital mortality.
Multivariate predictors
p  ˇ coefﬁcient OR 95% CI p R2
0.17 – – – –
0.99 – – – –
0.51 – – – –
0.71 – – – –
0.001 −0.08 0.921 0.843–1.006 0.07
0.01 −1.21 0.299 0.055–1.637 0.16
0.54 – – – –
0.92 – – – –
0.63 – – – – 0.41
0.65 – – – –
0.31 – – – –
<0.001 0.27 1.310 1.158–1.483 <0.001
<0.001 1.38 3.975 1.841–8.582 0.001
0.02 0.09 1.091 0.951–1.252 0.21
0.03 0.12 1.129 1.045–1.220 0.002
0.31 – – – –
0.32 – – – –
0.32 – – – –
jection fraction; BP, blood pressure.
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Fig. 2. The receiver-operating characteristic (ROC) curve for the neutrophil to lym-
phocyte ratio (N/L ratio) after levosimendan infusion, for predicting in-hospital
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mortality [area under the curve (AUC) = 0.737, 95% conﬁdence interval (CI):
.65–0.83; p < 0.001]. A N/L ratio value of at least 5.542 yielded a sensitivity of 67%,
 speciﬁcity of 66%.
eutrophil count and N/L ratio were observed only in patients who
ecovered (group 2) after the infusion of levosimendan. However,
he lymphocyte count was  decreased, while the N/L ratio and neu-
rophil count were signiﬁcantly increased, in patients who died
uring hospitalization. In addition, signiﬁcant amelioration of the
reatinine levels and serum hsCRP levels were detected in patients
ith a good clinical outcome after the infusion of levosimendan.
xperimental and clinical studies have shown that levosimendan
mproves renal function with a decline in serum creatinine levels
30,31]. Zemljic et al. [31] reported that levosimendan improved
ong-term renal function in patients with advanced chronic HF. In
heir study, an improvement in creatinine to ≥0.5 mg/dL occurred
n 50% of patients in the levosimendan group, compared with
0% of the controls (p = 0.005). In our study, a signiﬁcant decrease
n baseline creatinine levels was identiﬁed after the infusion of
evosimendan (1.3 ± 0.5 mg/dL vs. 1.2 ± 0.5 mg/dL; p = 0.005). The
ig. 3. Kaplan–Meier estimates for survival according to the N/L ratio after levosi-
endan therapy. N/L ratio, neutrophil to lymphocyte ratio.logy 63 (2014) 418–423
underlying mechanisms of the potential renoprotective effects of
levosimendan remain undeﬁned. Both improved cardiac output
and vasodilatation could lead to enhanced renal perfusion and
improved kidney function. Similarly, cardiac decompensation and
sustained damage to other organs because of a low cardiac output
and venous congestion can induce IL-6 production, which activates
hsCRP and complement resulting in ampliﬁcation of the inﬂamma-
tory response through TNF- production. This in turn may  lead to
a worsening of HF and unfavorable outcomes [32].
Our study demonstrated that increased N/L ratio after levosi-
mendan infusion was  an independent predictor of poor outcomes in
patients with ADHF. Furthermore, the predictive value of increased
N/L ratio was superior to other hematological parameters which
were previously demonstrated as predictors of morbidity and
mortality in these patients. In our study, higher N/L ratio after
levosimendan therapy was  associated with increased heart rate,
elevated serum creatinine and hsCRP levels, which were suggested
as independent predictors of mortality in patients with ADHF pre-
viously [33–35].
In light of these ﬁndings, the N/L ratio, which is an inexpen-
sive and readily obtainable parameter, could be used in clinical
practice as a useful marker of risk stratiﬁcation in patients admitted
with ADHF. Additional randomized, controlled trials are needed to
determine the prognostic role of the N/L ratio in ADHF patients.
Limitations
The major limitation of this study was the small popula-
tion size. Additionally, this was not a randomized and controlled
study; no detailed comparison with patients who received a
placebo or dobutamine was performed. Further, well known pro-
inﬂammatory and prognostic markers such as BNP, IL-6, IL-1,
TNF-, and cardiac troponin were not analyzed and compared with
the N/L ratio [20,21,36]. Thus, the results of this study should be
conﬁrmed in larger, prospective, randomized trials.
Conclusion
In conclusion, a high N/L ratio may  be used as a novel marker
of inﬂammation in the risk stratiﬁcation of patients with ADHF.
Our results demonstrate that a high N/L ratio on admission and
a lack of a decrease in the N/L ratio after levosimendan infusion
are associated with an increased risk of in-hospital mortality in
patients with ADHF. In addition to its favorable effects on cardiac
and hemodynamic measures, levosimendan could help to normal-
ize the impaired WBC  composition in these patients.
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